• Explore /
  • Poster
  • / Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience.

Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience.

Abstract Poster

Authors

null

Sanjana Ranganathan

Department of Urology, Houston Methodist Hospital, Houston, TX

Sanjana Ranganathan , Carlos Riveros , Jiaqiong Xu , Michael Geng , Emily Huang , Maryam Anis , Taliah Muhammad , Jun Zhang , Eleni Efstathiou , Christopher J.D. Wallis , Guru P. Sonpavde , Raj Satkunasivam

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer and Urothelial Carcinoma

Track

Urothelial Carcinoma,Prostate Cancer - Advanced

Sub Track

Quality of Care/Quality Improvement and Real-World Evidence

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 477)

DOI

10.1200/JCO.2023.41.6_suppl.477

Abstract #

477

Poster Bd #

H18

Abstract Disclosures

Similar Posters

First Author: Guillermo de Velasco

First Author: Chloe Lim

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Clinical outcomes for <em>IDH1</em> mutant biliary tract cancer (BTC) treated with contemporary systemic therapy.

Clinical outcomes for IDH1 mutant biliary tract cancer (BTC) treated with contemporary systemic therapy.

First Author: Darren Cowzer

First Author: Tamara A. Sussman